Home > News > Stock News > Detail
Bookmark and Share

Intellia nabs $10M from Novartis on expanded partnership

2018-12-07 01:21    Investing

Intellia nabs M from Novartis on expanded partnership Stock News

© Reuters. Intellia nabs $10M from Novartis on expanded partnership
  • Intellia Therapeutics (NTLA -0.8%) will receive $10M from partner Novartis (NVS -2.4%) on the basis of an expansion of their cell therapy collaboration into the ex vivo (out of the body) development of cell therapies using certain ocular stem cells.
  • NVS will have the right to develop CRISPR/Cas9-based products for one or more targets using the stem cells.
  • In addition to the $10M payment, NTLA will be eligible to receive milestones and royalties on net sales. Specific financial terms are not disclosed.
  • The companies' original partnership, inked in January 2015, will expire in December 2019 (including this expansion).
  • Now read: AbbVie (NYSE:ABBV): A Compelling Buy


0 traders reviewed this item, please leave a reply!

About FXYEAH | Broker Listing | Contribute | Contact Us | Sitemap | TagCloud
Disclaimer: All contents of site are only for your reference, don't suggest you do any investment decision, you should be responsible for your decision.